Transdel Pharmaceuticals and JH Direct have entered into a licensing agreement, providing JH Direct with the exclusive worldwide rights to Transdel’s anti-cellulite cosmeceutical product.
Under the agreement, JH Direct will pay Transdel initial royalty advances and a continuing licensing royalty on the worldwide sales of the anti-cellulite product. Transdel has retained the exclusive rights to seek pharmaceutical/dermatological partners for the anti-cellulite product, for an initial period of one year.
Juliet Singh, President and CEO of Transdel, said: We are extremely pleased with our relationship with JH Direct and plan on building on this relationship to launch additional cosmeceutical products. This venture is very exciting as we believe it could represent the beginning of what may become a revenue stream for Transdel. An estimated 85% to 90% of women develop cellulite following puberty. The size of this target market combined with the desire to remove cellulite represents a $3 billion market and thus provides a promising market opportunity.
We also plan on expanding our pipeline to include formulations for anti-aging, varicose vein and hyperpigmentation cosmetic/cosmeceutical products,” she added.